Assignee

LUDWIG INST CANCER RES

US396 patents

Top patents by PatentIndex Score

US6245530B1Jun 12, 2001

Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these

LUDWIG INST CANCER RES86 citations98

US6342587B1Jan 29, 2002

A33 antigen specific immunoglobulin products and uses thereof

LUDWIG INST CANCER RES93 citations98

US6235713B1May 22, 2001

Vascular endothelial growth factor-D (VEGF-D) polypeptides

LUDWIG INST CANCER RES113 citations98

US5840693ANov 24, 1998

Vascular endothelial growth factor-B

LUDWIG INST CANCER RES156 citations98

US5607918AMar 4, 1997

Vascular endothelial growth factor-B and DNA coding therefor

LUDWIG INST CANCER RES239 citations98

US5405940AApr 11, 1995

Isolated nonapeptides derived from MAGE genes and uses thereof

LUDWIG INST CANCER RES129 citations98

US5342774AAug 30, 1994

Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

LUDWIG INST CANCER RES232 citations98

US7314721B2Jan 1, 2008

Small cell lung cancer associated antigens and uses therefor

LUDWIG INST CANCER RES111 citations97

US6383484B1May 7, 2002

Antibodies to truncated VEGF-D and thereof

LUDWIG INST CANCER RES115 citations97

US6274710B1Aug 14, 2001

Antibodies which specifically bind T Cell inducible factors (TIFs)

LUDWIG INST CANCER RES94 citations97

US5830753ANov 3, 1998

Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.

LUDWIG INST CANCER RES82 citations97

US5716930AFeb 10, 1998

Glial growth factors

LUDWIG INST CANCER RES109 citations97

US5530109AJun 25, 1996

DNA encoding glial mitogenic factors

LUDWIG INST CANCER RES136 citations97

US6689580B1Feb 10, 2004

Growth factor

LUDWIG INST CANCER RES59 citations96

US6548064B1Apr 15, 2003

Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules

LUDWIG INST CANCER RES51 citations96

US6235525B1May 22, 2001

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof

LUDWIG INST CANCER RES27 citations96

US6130052AOct 10, 2000

Leukemia associated genes

LUDWIG INST CANCER RES89 citations96

US6034214AMar 7, 2000

Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells

LUDWIG INST CANCER RES40 citations96

US6025191AFeb 15, 2000

Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof

LUDWIG INST CANCER RES35 citations96

US6022692AFeb 8, 2000

Method for screening for possible presence of cancer

LUDWIG INST CANCER RES38 citations96

US5965535AOct 12, 1999

Mage-3 peptides presented by HLA class II molecules

LUDWIG INST CANCER RES51 citations96

US5824492AOct 20, 1998

Polypeptides having kinase activity, their preparation and use

LUDWIG INST CANCER RES127 citations96

US5681751AOct 28, 1997

Method allowing sequential chemical reactions

LUDWIG INST CANCER RES107 citations96

US5620886AApr 15, 1997

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

LUDWIG INST CANCER RES75 citations96

US5571711ANov 5, 1996

Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors

LUDWIG INST CANCER RES69 citations96

US5462871AOct 31, 1995

Isolated nucleic acid molecules which encode MAGE derived nonapeptides

LUDWIG INST CANCER RES52 citations96

US5342757AAug 30, 1994

Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof

LUDWIG INST CANCER RES69 citations96

US7589180B2Sep 15, 2009

Specific binding proteins and uses thereof

LUDWIG INST CANCER RES70 citations95

US6692925B1Feb 17, 2004

Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use

LUDWIG INST CANCER RES110 citations95

US6482623B1Nov 19, 2002

Lipid kinase

LUDWIG INST CANCER RES140 citations95

US6331301B1Dec 18, 2001

Antibodies specific for vascular endothelial growth factor-B

LUDWIG INST CANCER RES58 citations95

US6096313AAug 1, 2000

Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant

LUDWIG INST CANCER RES56 citations95

US5928939AJul 27, 1999

Vascular endothelial growth factor-b and dna coding therefor

LUDWIG INST CANCER RES65 citations95

US5683886ANov 4, 1997

Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof

LUDWIG INST CANCER RES51 citations95

US5648226AJul 15, 1997

Isolated peptides derived from tumor rejection antigens, and their use

LUDWIG INST CANCER RES72 citations95

US5612201AMar 18, 1997

Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor

LUDWIG INST CANCER RES127 citations95

US5585461ADec 17, 1996

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

LUDWIG INST CANCER RES39 citations95

US5487974AJan 30, 1996

Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

LUDWIG INST CANCER RES59 citations95

US5280109AJan 18, 1994

Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2

LUDWIG INST CANCER RES44 citations95

US7034105B2Apr 25, 2006

FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy

LUDWIG INST CANCER RES47 citations94

US6359117B1Mar 19, 2002

Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses therefor

LUDWIG INST CANCER RES73 citations94

US6291430B1Sep 18, 2001

Mage-3 peptides presented by HLA class II molecules

LUDWIG INST CANCER RES48 citations94

US5594114AJan 14, 1997

Schwann cell mitogenic factor, its preparation and use

LUDWIG INST CANCER RES61 citations94

US5229495AJul 20, 1993

Substantially pure receptor like TGF-β 1 binding molecules and uses thereof

LUDWIG INST CANCER RES64 citations94

US6849420B2Feb 1, 2005

Method for determining modulation of p110δ activity

LUDWIG INST CANCER RES95 citations93

US6800730B1Oct 5, 2004

Isolated peptides which bind to MHC class II molecules, and uses thereof

LUDWIG INST CANCER RES14 citations93

US6057115AMay 2, 2000

Process for producing GM2 specific antibodies

LUDWIG INST CANCER RES21 citations93

Showing the top 50 of 396 patents by PatentIndex Score.

LUDWIG INST CANCER RES

Top patents by PatentIndex Score

Receptor ligand

Method for identifying auto-immunoreactive substances from a subject

MAGE-A4 antigenic peptides and uses thereof

Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these

A33 antigen specific immunoglobulin products and uses thereof

Vascular endothelial growth factor-D (VEGF-D) polypeptides

Vascular endothelial growth factor-B

Vascular endothelial growth factor-B and DNA coding therefor

Isolated nonapeptides derived from MAGE genes and uses thereof

Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Small cell lung cancer associated antigens and uses therefor

Antibodies to truncated VEGF-D and thereof

Antibodies which specifically bind T Cell inducible factors (TIFs)

Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.

Glial growth factors

DNA encoding glial mitogenic factors

Growth factor

Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof

Leukemia associated genes

Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells

Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof

Method for screening for possible presence of cancer

Mage-3 peptides presented by HLA class II molecules

Polypeptides having kinase activity, their preparation and use

Method allowing sequential chemical reactions

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors

Isolated nucleic acid molecules which encode MAGE derived nonapeptides

Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof

Specific binding proteins and uses thereof

Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use

Lipid kinase

Antibodies specific for vascular endothelial growth factor-B

Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant

Vascular endothelial growth factor-b and dna coding therefor

Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof

Isolated peptides derived from tumor rejection antigens, and their use

Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2

FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy

Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses therefor

Mage-3 peptides presented by HLA class II molecules

Schwann cell mitogenic factor, its preparation and use

Substantially pure receptor like TGF-β 1 binding molecules and uses thereof

Method for determining modulation of p110δ activity

Isolated peptides which bind to MHC class II molecules, and uses thereof

Process for producing GM2 specific antibodies